GLP1R and cancer: An additional retrospective study of 1,651,452 individuals with T2D in the United States demonstrated that treatment with GLP-1R agonists in comparison to insulin was associated with a decreased incidence in 10 of 13 obesity-associated cancers including pancreatic (HR 0.41; 95%CI: 0.33-0.50), colorectal cancer (HR 0.54; 95%CI: 0.42-0.86), ovarian cancer (HR 0.52; 95%CI: 0.03-0.74), and multiple myeloma (HR 0.59; 95%CI: 0.44-0.77)[11].